Psilocybin, in 10 mg or 25 mg doses, has no short- or long-term detrimental effects in healthy people Patrick O'Brien King’s College London News Center, 2022 https://www.kcl.ac.uk/news/psilocybin-in-10mg-or-25mg-doses-has-no-short-or-long-term-detrimental-effects-in-healthy-people Psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously. New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King’s College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously. The research, published in The Journal of Psychopharmacology, is an essential first step in demonstrating the safety and feasibility of [...]
Lire la suiteAssessing the risk-benefit profile of classical psychedelics : a clinical review of second-wave psychedelic research David Bender & David J. Hellerstein Psychopharmacology (Berl), 2022. Doi : 10.1007/s00213-021-06049-6 Abstract Rationale : A broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use. Objectives : To use recently published data to assess potential risks and benefits of psychedelic drugs as therapeutics, as well as to synthesize what is currently known in order [...]
Lire la suitePsychedelic Therapy and Suicide : A Myth Busted ? Megan Brooks Medscape Psychiatry, February 01, 2022 www.medscape.com/viewarticle/967669_print A commonly held belief that classic psychedelic therapy can trigger suicidal thoughts, actions, or other types of self-harm is not supported by research, and, in fact, the opposite may be true. Results from a meta-analysis of individual patient data showed that psychedelic therapy was associated with large, acute, and sustained decreases in suicidality across a range of clinical patient populations. "This is the first analysis to synthesize suicidality outcome data from recent clinical trials with psychedelics. It gives us a better understanding of the effects of psychedelics on suicidality in the [...]
Lire la suite